Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418492 | 0.86 | AKR1C4 (0.57) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL420185 | 0.84 | SERPINE1 (0.77) | MAPTAKR1C2AKR1C1AKR1C4AKR1C3 | |
| SCHEMBL267931 | 0.83 | HPGD (0.57) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL269119 | 0.82 | F10 (0.55) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL421465 | 0.81 | SERPINE1 (0.65) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL3049009 | 0.81 | GFER (0.61) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL7040635 | 0.81 | ACLY (0.61) | MAPTAKR1C2AKR1C1KMT2AAKR1C4 | |
| SCHEMBL31454340 | 0.80 | MAPT (0.72) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL14075415 | 0.80 | MAPT (0.72) | MAPTAKR1C2AKR1C1MEN1KMT2A | |
| SCHEMBL417914 | 0.80 | SERPINE1 (0.64) | MAPTAKR1C2AKR1C1AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | GRIK1 3080/4885MAPT 2976/4885AKR1C2 813/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | GRIK1 3080/4885MAPT 2976/4885AKR1C2 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.